IPC will use the information you provide on this form to send you information about psoriasis. You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by emailing info@psoriasiscouncil.org. By clicking the subscribe button, you agree that we may process your information in accordance with our privacy policy . We use Mailchimp as our marketing automation platform. By clicking the subscribe button to submit this form, you also acknowledge the information you provide will be transferred to Mailchimp for processing in accordance with their privacy policy and terms.
In the latest Psoriasis Review IPC's bi-annual review of the latest news in the field of psoriasis. Read the latest issue
Latest news Video Series on IPC’s Psoriasis Severity ReclassificationMarch 30, 2021Learn how psoriasis severity is currently measured and why a change is necessary, how IPC organized the Delphi process that was used to redefine severity classification, implications and effects the output has on psoriasis treatment providers and psoriasis patients, and ultimately how patients will benefit from this endeavor. Janssen Phase-3 TREMFYA® Clinical TrialMarch 29, 2021Janssen Pharmaceutical Companies of Johnson & Johnson published the long-term data of the third phase of the DISCOVER-2a study. Sun Pharma Phase-3 ILUMYA® Clinical TrialMarch 28, 2021Sun Pharmaceutical Industries Inc. announces results from their five-year Phase-3 efficacy and safety clinical trial for ILUMYA®(tildrakizumab-asmn) based on a pooled analysis of the ReSURFACE 1 and ReSURFACE 2 extension. Update on PsoProtect Registry DataMarch 17, 2021Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1002 cases. More News